Media stories about Anacor Pharmaceuticals (NASDAQ:ANAC) have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Anacor Pharmaceuticals earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.4700060493996 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the media stories that may have effected Accern Sentiment’s analysis:
- Contact Dermatitis – Pipeline Review, H1 2017 including Key Player Anacor Pharmaceuticals Inc, AskAt Inc, Brickell … – Medgadget (blog) (medgadget.com)
- Atopic Dermatitis Treatment Market to Manage U$ 23,992.3 Mn in Revenues by 2027-End (openpr.com)
- Persistent Facial Erythema Treatment Market By New Report For The Forecast 2017 – 2025 – satPRnews (press release) (satprnews.com)
COPYRIGHT VIOLATION WARNING: This report was reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/2798006/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-anacor-pharmaceuticals-anac-share-price.html.
Anacor Pharmaceuticals Company Profile
Anacor Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis.
Receive News & Ratings for Anacor Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anacor Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.